Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

2014 ASCO Annual Meeting

Published: 31 May 2014

Views: 2553

Rating:

Save

Dr John Byrd - The Ohio State University, Columbus, USA

At a press conference at ASCO 2014, Dr Byrd presents the early findings from the phase III RESONATE study which indicate that ibrutinib yields lasting tumour responses and marked improvement in survival over standard of atumumab for patients with relapsed chronic lymphocytic leukaemia (CLL).

Read the article for more.

Related Videos

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse...

Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA

$Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma ( Dr Jeremy Abramson - Mass General Cancer Center, Boston, USA )$

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

The current status of multiple myeloma diagnosis and treatment

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

The current status of multiple myeloma diagnosis and treatment ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )

The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation...

Dr Jayant Vaidya - University College London, London, UK

The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival ( Dr Jayant Vaidya - University College London, London, UK )

More from ecancer